samedan logo
 
 
 
spacer
home > ebr > spring 2017 > editor’s letter
PUBLICATIONS
European Biopharmaceutical Review

Editor’s Letter

Proteins, proteins, proteins. They are a main feature in our spring edition of EBR – perhaps not surprisingly, considering the continued increase in adoption to clinical practice of high-value, high-performing protein therapeutics and the need for their manufacture at scale by the biopharmaceutical industry.

Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab would argue that, considering the market size and recent numbers of US and European approvals in these drug classes, the future for mid-size contract development and manufacturing organisations lies in complex proteins or ‘modern biopharmaceuticals’; monoclonal antibodies and proteins for cancer and autoimmune conditions in particular (see full pdf). In their articles, Christian Loch from AVMBioMed (see full pdf) and Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye (see full pdf) agree that, at present, proteomics is the best means for capturing this vital information.

AVMBioMed highlight the need to consider the importance of post-translational modification in defining the human protein repertoire, and the Trinean team plus Kris Gavaert and Francis Impens flag the need for further improvements in quality to move proteomics towards a unified regulatory process.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement